Agent possessing anti-inflammatory and antiallergic action

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacy, medicine and veterinary science, particularly new drugs for inflammatory and allergic diseases. The assigned problem preparing a non-toxic, easy-to-use and storage-stable drug in the form of eye drops, intranasal drops and spray and causing anti-inflammatory and antiallergic action is solved by creating a composition containing a pigment-mineral complex of sea-urchin shell (0.05-2.0%) containing spinochromes B, D, dimer polyhydroxynaphthoquinone and a mineral ingredient (calcium, magnesium, phosphor, sodium, potassium) in the form of water-soluble salts, a co-solvent (0.01-10%), a preserving agent (0.01-0.2%), an antioxidant (0.01-0.2%), an acidity regulator (to pH 6.0-8.0) and water (to 100%).

EFFECT: what is described is the experimentally specified method for preparing the agent according to the invention eliminating the oxidation of the pigment-mineral complex as early as the stage of preparing.

3 cl, 3 tbl, 1 dwg, 6 ex

 

The invention relates to the field of pharmacy, medicine and veterinary medicine, namely to new medicines for the treatment of inflammatory and allergic diseases.

Edible sea urchins, in addition to the field object for the food industry, are a rich source of unique biologically active substances. Such substances include polyhydroxyalkanoate pigments armor and needles sea urchins - spinorama. Unlike endogenous antioxidants, such as vitamin E and ubiquinone, naftochinona able to neutralize the action of the main initiators of the nonenzymatic oxidation of membrane lipids - cations of iron accumulating in the area of ischemic tissue damage. These features of the mechanism of action allocate spinorama from a number of known bioantioxidants and offer the prospect for creation on their basis of drugs of new generation.

Known composition containing derivatives of natural or synthetic polyhydroxyalkanoic (alkyl-, hydroxyalkyl-, acyl-, nitro-, amino -, or halogen derivatives) with funghi, algo, Gerbi and bactericidal properties (Pat. Appl. GB2159056A, publ.27.11.1985).

Renowned pharmaceutical composition comprising as active ingredient an ethyl acetate extract of the shells of sea urchins, with anticommunication and recommended in hypertension and diseases of the cardiovascular system, associated with increased thrombosis, such as myocardial infarction, stroke, etc. (Pat. Appl. KR20020091909A, publ. 11.12.2002).

The acetone extract of the shells of sea urchins Strongylocentrotus nudus is included in the pharmaceutical composition, the use of which is recommended to reduce total cholesterol and hypertension, diseases of the cardiovascular system and disorders of cerebral circulation (Pat. Appl. KR 20020085543 AND, publ. 16.11.2002).

Known biologically active additives (BAA) to food with gipolipidemiceski and antioxidant, containing in its composition extract flat sea urchins, containing 0,75-0,85% echinochrome A (Pat. EN 2340216 C1, publ. 10.12.2008).

Known composition containing an extract of the gonads, intestines or shells of sea urchin (Anthocidaris crassispina, Hemicentrotus pulcherrimus, Pseudocentrotus depressus or Strongylocentrotus internmedius} for the prevention and treatment of liver diseases with antioxidant and detoxifying benefits (Pat. Appl. KR20110001251 A, publ. 06.01.2011).

Alcohol solution containing echinochrome And in complex with chitosan, ascorbic, lipoic, citric and succinic acids used for the correction of the pathological disorders of carbohydrate, lipid and antioxidant status of the organism(Pat RU2360683 C1, publ. 16.04.2008).

The closest to this invention is the preparation Histogram used for treatment in policlinic diseases of the retina and cornea of the eye, representing 0.02% of the isotonic solution of di - and tinatawag salts pigment from the group of spinorama - echinochrome A (Pat. EN 2134107 C1, publ. 10.08.1999).

The objective of the invention is the creation of products containing as the active component of the biologically active complex obtained from shells and needles of green sea urchins Strongylocentrotus droebachiensis, containing from 0.02% to 10% pigment complex containing spinorama b and D, as well as dimeric polyhydroxyalkane and from 7.5% to 20% of the mineral component of the shells of sea urchins (calcium, magnesium, phosphorus, sodium, potassium) in the form of water-soluble salts, for local application in the form of eye drops, intranasal drops and spray that has anti-inflammatory and antiallergic action, non-toxic, easy to use and stable during storage.

The problem is solved by the creation of funds in the following components in grams per 100 g:

Pigment and mineral complex - 0,05-2,0;

The co-solvent is from 0.01 to 10;

Preservative - 0,01-0,2

Antioxidant - 0,01-0,2

Acidity regulator-to solution pH of 6.0-8.0

Water up to 100.

The method of obtaining funds is as follows: the preservative is mixed with water for injection at a temperature of 80-90°C and stirred until complete dissolution. After cooling to a temperature of 35-40°C to RA is Toru add the calculated amount of co-solvent, antioxidant and stirred to obtain a clear solution. Then the solution is injected pigment and mineral complex and bring the solution pH to 6.0 to 8.0 with acidity regulator. The solution is filtered and poured into vials. If necessary, conduct sterilization.

In particular for sterilization can be used for sterile filtration or thermal sterilization by steam under pressure.

We found that the order of mixing the ingredients is essential to ensure stability of the pigment and mineral complex. It has a high redox potential and is easily oxidized. To ensure the pharmacological activity of pigment and mineral complex, such as the inhibition of free radical oxidation of lipids of cellular membranes, modulation of prostaglandin synthesis, increased activity of antioxidant enzymes of the body, etc. needed his protection from oxidation during preparation, storage. Experiments have shown that a significant factor for the stability of the composition during storage is the introduction of its antioxidant, which offers sodium metabisulfite, sodium sulfite, sodium thiosulfate or ascorbic acid.

Use in the composition of pigment and mineral what about the complex at a concentration of 0.05-2.0 wt.% provides therapeutic activity and good tolerability of the drug. The increase of its concentration above the specified limit is undesirable and leads to a change isotonicity and isolationist solution, and is not economically justified.

Empirically we found that the introduction of the means of preservative needed to create stable over a long period of time (not less than 2 years) composition of pigment and mineral complex in the form of a solution, and taking into account multiple use after opening the package, contributing to microbial contamination. As preservative can be used pharmaceutically acceptable preservatives such as p-hydroxybenzoate lower Akilov (for example, nipagin, nipazol), chlorhexidine in the form of the acetate or gluconate and pharmaceutically applicable Quaternary ammonium compounds (benzalkonium chloride and/or benzogexonia).

Part of the funds entered a co-solvent, which can improve if necessary the concentration of pigment and mineral complex comprising means improves the bioavailability of the active substance. As a co-solvent can be used pharmaceutically acceptable solvents, such as ethyl alcohol, Polysorbate 80, polyethylene glycol, propylene glycol, glycerol, polyoxyethylene-40-glycerol-hydroxystearate, monotropy ether of diethylene glycol, polyvinyle the Lydon, polyvinyl alcohol.

Introduction acidity regulator implemented with the aim of creating a comfortable cell environment, without causing damage or burning. Use of sodium salts of carbonic acid, ethylenediaminetetraacetic acid in the form of three-, Terentieva salts, sodium hydroxide, as the most appropriate liquid media of the body.

The technical result provided by the present invention is the application of pigment and mineral complex derived from shells and needles sea urchins, as a means, which has anti-inflammatory and anti-allergic effect by blocking H1 histamine receptors.

Given a set of distinctive features of the proposed method are not described in literature, and their influence on the achievement of the technical result does not follow from the known level of knowledge in the field of production technology of medicinal drugs.

The technical result of the invention is to secure funds on the basis of pigment and mineral complex in the form of finished dosage forms for local application (drops or spray) with a pronounced therapeutic effect. A new property of the pigment and mineral complex from shells and needles sea urchins established by the authors for the first time experimentally.

The composition of the pigment and mineral complex is directly dependent on the method of obtaining (Pat. RU # 2441661 (C1), publ. 10.02.2012).

Thus, the proposed solution meets the criteria of the invention, namely of "novelty", "inventive step" and "industrial applicability".

The possibility of implementing the claimed invention is shown, but are not limited to, the examples of specific performance.

Example 1. Eye drops (in g per 100 g). In a suitable vessel with a stirrer, a thermostatted at 80-90°C in 91,9 ml of water for injection is dissolved 0.1 g of nipagin. The resulting solution was cooled to a temperature of 35°C, add 0.1 g of ascorbic acid, mix, add 3.5 g of ethyl alcohol, stirred to obtain a clear solution. In solution give 0.05 g of the pigment and mineral complex, and adjusting the pH by addition of 4.35 g of sodium bicarbonate. After receive filtering solution with a pH of about 6.2. Spend bottling in glass bottles with a volume of 5 ml, followed by sterilization in an autoclave at a temperature of 100°C for 30 minutes. Get 19 bottles (including losses) in 5 ml of eye drops containing 0.05% pigment and mineral complex.

Example 2. Drops nasal, spray (in g per 100 g). In a suitable vessel with a stirrer, a thermostatted at 80-90°C, 93,4 ml of water for injection is dissolved 0.05 g of chloride is enthaltene. The resulting solution was cooled to a temperature of 35°C, add 0.15 g of sodium metabisulfite, 2.5 g of polyvinylpyrrolidone are mixed to obtain a transparent solution. In the resulting solution make 1.0 g of pigment and mineral complex, and adjusting the pH of the resulting solution to 7.0 by the addition of 2.9 g of ethylenediaminetetraacetic acid in the form of dihydrate disodium salt. After receive filtering solution with a pH of about 7. The finished solution is filtered, subjected to sterilizing filtration in a stream of nitrogen and then poured and sealed under aseptic conditions in penicillin dark glass bottles with dispensers-dropper or spray nozzle for spray volume of 5 ml Get 19 bottles (including losses) in 5 ml containing 1.0% of pigment and mineral complex.

Example 3. Antiallergic activity in vivo model of allergic conjunctivitis.

Allergic conjunctivitis (AC) induced by topical application of 0.1 ml of the solution "Compound 48/80" (10 mg/ml) on the conjunctiva of the eye rabbit (grey chinchilla). The tool of example 1 with the content of the pigment and mineral complex in the amount of 0.05% and the Comparators of Patanol (0.1% solution olopatadine hydrochloride) and Histogram introduced intracrystalline 0.05 ml in treatment-and-prophylactic scheme: 1 times a day for 3 days prior to induction Pat the technology and over 10, 30, 45 and 100 minutes after the induction of pathology.

The condition of the surface structures and the anterior eye was assessed by a scoring system (Miyazaki et at. Conjunctival mast cell as a mediator of eosinophilic response in ocular allergy // Mol. Vis. 2008. 14. 1525-1532) indicators: swelling of the conjunctiva, swelling of eyelids, lacrimation, conjunctival injection before applying and after 5, 15 minutes, 1, 2 and 24 hours after application of the solution of Compound 48/80 (figure 1).

Antiallergic activity funds in example 1 in all studied indicators exceeded the activity of the Comparators. When the total scores for the entire period of observation found that the anti-Allergic activity funds in example 1 in respect of external signs of allergic conjunctivitis is almost 3 times higher than that of Histogram and 50 percent exceeds antiallergic activity Patanol.

Example 4. The influence of money on the sensitivity of the H1-histamine receptors ex vivo

Experiments with isolated tissues allow to obtain a full and accurate data about the direction and mechanism of action of certain neurotransmitters directly on the receptor apparatus of the tissues and organs.

The ability of the funds in example 1 with the content of the pigment and mineral complex in the amount of 0,05% contact H1-histamine receptors was evaluated by the method of the histamine-induced is ukrasheniya ileum of the Guinea pig.

The terminal ileum was removed from the abdominal cavity of anesthetized animals were placed in a container cooled to+4°C buffer Krebs-Henseleit (BCH). Then the terminal ileum was cut into slices about 1 cm in length, fragments mounted in flow-through chambers and perfesional oxygendemanding BCH at a temperature of +30°C for 60 minutes, then the flow chamber was filled with 80 mM KCl, which caused a strong reduction of the segments of the intestine. The obtained results were further taken for 100% reduction.

Renewed perfusion oxygendemanding BCH at a temperature of +30°C for washing fabrics and restore their ability to decrease. After 60 minutes of washing was performed perfusion with the solution of example 1 in BK. The concentration of funds in example 1 in the final solution ranged from 1 to 10 μl/ml as the comparison drug used pyrilamine maleate (10 μm). After a thirty minute incubation period, the solutions were decanted, and the flow chamber was filled with an aqueous solution of histamine (1 μm). Within 10 minutes was registered power reduction, estimated the amplitude and time of occurrence of maximum response (table 1).

Table 1
The amplitude of the histamine-induced is ukrasheniya and time of occurrence of maximum response (Me±Q, n=8)
GroupDoseAmplitude (% of reduction at 80 mm KCl)Time (percentage of time reduction at 80 mm KCl)
Control (histamine)1 micron100,81±10,35**1,32±0,38**
Pyrilamine maleate10 µm5,72±4,79*10,22±3,96*
The tool according to example 11 µl/ml69,10±20,22*,**3,45±2,54*,**
The tool according to example 15 µl/ml42,15±11,57*,**5,19±3,02*
The tool according to example 110 µl/ml26,49±8,33*,**to 10.09±2,71*
* values are statistically significant compared to control group at p<0,05
** values are statistically significant compared with group pyrilamine maleate, at p<0,05

The tool according to example 1 in all predlozhenietaiwan was blocking H1-histamine receptors proteins in smooth muscle of the ileum. Effective dose (ED50) funds in example 1 was 2,97 ál/ml

Thus, the tool of example 1 is effective in blocking H1-histamine receptors.

Example 5. Anti-inflammatory activity in vivo in a model of acute rhinosinusitis (LFS) in rats.

The experiment was carried out in rats male Wistar weighing 220-270 g, maintained on a standard diet. The induction of pathology was performed by intranasal introduction of 7.5% formalin for 20 μl in each nostril. Pathology was characterized by plethora, hyperplasia, and focal necrosis of the mucous membrane of the nasal passages, increasing the number of goblet cells, infiltration mononeucleosis and leukocytes, mucus hyperproduction of submucosal glands shell.

The tool according to example 2 with the content of the pigment and mineral complex of 1% was imposed on medical scheme within 7 days of once daily, administered in a dose of 0.025 ml in each nostril. The Comparators Vibrozil and Aqua Maris was introduced in the same way in doses of 0.1 ml in each nostril. On the 8th day after the induction of pathology animals were subjected to euthanasia and comparative macroscopic and morphological studies of the mucous and submucous membranes of the nasal passages (table 2).

Pathology caused by intranasal introduction of 7.5% formalin was characterized by catarrhal form of rhinosinusitis. When used according to example 2 was observed cure 30% of the experimental animals. The Comparators in the model were not effective and the background of their application was developed serous rhinosinusitis in 70-80% of the animals and serous-purulent rhinosinusitis in 20% of animals. Application of tools for example 2 prevented the development of severe forms of inflammation of the mucous membrane of the nasal passages.

On the background of the application means according to the example 2 was significantly decreased number of goblet cells per 1 mm of the mucous membrane of the nasal passages, and leukocyte infiltration of the submucosal membrane was intact group of animals.

Thus, pharmacological activity funds according to example 2 in a model of acute rhinosinusitis exceeds the activity as local anti-inflammatory agents Aqua Maris and anticongestive, vasoconstrictor and anti-allergic medicines Vibrozil.

Example 6. Antioxidant activity

It is known that in allergic processes increases the rate of free radical oxidation (Simonyan AV Antioxidants in modern healthcare. // Medical Bulletin. - 2008. No. 16. - 443). Thus, the antioxidant effect of antiallergic drugs is the additional advantage of making the system shall mnost of action of the drug.

The impact tool according to the example 2 on the antioxidant status of the organism studied on the model of streptozotocin-induced type 2 diabetes.

The experiment was carried out on outbred mice-males. The induction of pathology was carried out by a single introduction of streptozotocin (60 mg/kg). In the period from 11 to 20 days was carried out by intraperitoneal injection of funds according to example 2 with the content of the pigment and mineral complex 1% in quantity, ensure the introduction of the complex in the amount of 1.8 mg/kg, which corresponds to a dose of 10 mg for humans. The impact tool according to the example 2 on the antioxidant status of the organism was assessed by the change in the concentration of reduced glutathione and malondialdehyde in the peripheral blood (table 3).

Table 3
The impact tool according to the example 2 on the antioxidant status of the organism (M±m)
GroupThe concentration of reduced glutathione, mmol/mlThe concentration of malondialdehyde, umol/l
Intact (n=10)0,60±0,0411,1±0,4
Control (pathology+placebo)1 (n=9)0,26±0,06*19,0±1,3*
Product sample 2 (n=10)0,66±0,05**9,4±0,6*,**
1placebo - water
* - the differences are statistically significant compared to non-treated group at p<0,05
** - the differences are statistically significant compared with the control group at p<0,05;

The increase in the concentration of malondialdehyde and reduced the concentration of reduced glutathione in peripheral blood of experimental animals of the control group shows the development of oxidative stress on the background of the introduction of streptozotocin.

The tool according to example 2 had pronounced antioxidant effect, is to increase the concentration of reduced glutathione and a decrease in the concentration of malondialdehyde and restore them to the level of intact animals.

Thus, funds in example 1 and 2 extend the range of safe, effective anti-inflammatory and antiallergic agents from natural sources.

1. The tool, which has anti-inflammatory and antiallergic effect, in the form of eye cap is l, intranasal drops or spray containing the active substance, the co-solvent, preservative, acidity regulator and water, characterized in that it further comprises an antioxidant selected from the group of sodium metabisulfite, sodium sulfite, sodium thiosulfate or ascorbic acid, a co-solvent selected from the group of ethyl alcohol, Polysorbate 80, polyethylene glycol, propylene glycol, glycerol, polyoxyethylene-40-glycerol-hydroxystearate, monotropy ether of diethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol as the active substance contains a pigment complex shells of sea urchins Strongylocentrotus droebachiensis (0,02-10%), containing spinorama b and D, as well as dimeric polyhydroxyalkane, and mineral component of the shells of sea urchins (calcium, magnesium, phosphorus, sodium, potassium) in the form of water soluble salts and acidity regulator in the following ratio of components, g per 100 g:

Pigment and mineral complex0,05-2,0
The co-solvent0,01-10
Preservative0,01-0,2
Antioxidant0,01-0,2
Acidity regulator on the solution pH 6,0-8,0
Waterup to 100.

2. The method of obtaining the means according to claim 1, characterized in that it includes
following stages:
a) preparation of a solution of the preservative in water at 80-90°C, cooling the resulting solution to 35-40°C;
b) dissolving in a chilled solution of co-solvent and oxidant to obtain a clear solution;
C) introduction of pigment and mineral complex in the resulting solution of auxiliary substances with constant stirring;
g) introduction of acidity regulator and bringing the pH of the solution to 6.0 to 8.0;
d) filtering the resulting solution and pour into bottles.

3. The method of receiving according to claim 2, characterized in that the sterilization can be used for sterile filtration or thermal sterilization by steam under pressure.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to field of pharmaceutics and medicine and deals with medication for treatment or prevention of diseases, mediated by mast cells, including neramexane or its pharmaceutically acceptable salt.

EFFECT: medication has high efficiency with respect to treatment or prevention of diseases, mediated by mast cells.

28 cl, 1 dwg, 17 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a multidose ophthalmic composition containing prostaglandin as a therapeutic ingredient, mannitol or sorbitol 0.15-0.5 wt/vol %, propylene glycol or glycerol 0.2-1.8, borate 0.25-0.5 wt/vol %, an antimicrobial preserving agent 0.0003-0.003 wt/vol % representing a polymer quaternary ammonium compound and water. Said composition has pH 6.4-7.2 and is benzalconium chloride free. Besides, the invention refers to the use of said ophthalmic composition for preparing a drug for treating glaucoma, eye infections, allergies and inflammations.

EFFECT: preparing the ophthalmic composition which exhibits improved antimicrobial preserving activity and improved buffer properties.

16 cl, 8 tbl, 21 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to a piperidine derivative of general formula (I)

,

where R1 denotes hydrogen or a substitute selected from the following (b)-(i): b) acrylic acid (including alkyl ester and hydroxyalkyl amide), (c) ureide, (d) alkenyl, (e) aminoalkyl which can be substituted with alkyl carbonyl or aminocarbonyl, (f) carbonyl alkyl, substituted with hydroxy, alkoxy or hydroxyalkylamino, (g) carbonyl, substituted with hydroxy, morpholino, alkoxy, hydroxyalkyl aminoalkoxy or cyclohexyloxy carbonyloxyalkoxy, (h) carbonylamino, substituted with alkyl or alkoxy, (i) aminocarbonyl which can be substituted with one or two substitutes selected from amino, hydroxy, alkoxy, alkenyl and alkyl (which can be substituted with halogen, thiol, piperidino, amino, alkoxy, alkoxycarbonyl, aminocarbonyl or one or two hydroxy); R2 denotes hydrogen or a substitute selected from the following (j)-(r): (j) cyano, (k) acrylic acid, (l) alkyl, substituted with hydroxy or piperidino, (m) carbonyl alkyl, substituted with hydroxy, alkoxy (which can be substituted with cyclohexyloxy carbonyloxy) or hydroxyalkylamino, (n) carbonyl, substituted with hydroxy or alkoxy, (o) carbonyl alkoxy, substituted with alkoxy, (p) carbonyl alkyl sulphanyl, substituted with hydroxy or alkoxy, (q) alkoxy, (r) halogen; and R3 denotes hydrogen or a substitute selected from the following (s)-(w): (s) alkyl which can be substituted with carboxy, cyano, pyrrolidyl, piperidino, alkoxy, alkyl sulphanyl or one or two hydroxy, (t) carbonyl, substituted with alkyl or alkoxy, (u) carbonyl alkoxyalkyl, substituted with hydroxy or alkoxy, (v) carbonyl alkyl, substituted with alkyl, alkoxy or alkylphenyl, (w) aminoalkyl, substituted with aminocarbonyl or alkane sulphonyl, where one of said R1 and R2 denotes a substitute other than hydrogen, A is unsubstituted or is an oxo, B denotes carbon or oxygen, one of X and Y denotes carbon and the other denotes sulphur, the dotted line denotes a single bond or a double bond, under the condition that when R2 denotes halogen or alkoxy, A is unsubstituted, R1 denotes a substitute other than hydrogen and B denotes oxygen. The invention also relates to an antihistamine which contains a compound of formula I and use of the described compound for treatment and production of a medicinal agent.

EFFECT: novel compounds having antagonistic action on histamine receptors are obtained and described and can be suitable as active ingredients of a pharmaceutical composition, especially an antihistamine composition.

17 cl, 40 ex, 21 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to method of obtaining said salts, to pharmaceutical composition, containing said salts, and to application of salt for preparation of medication for treatment, prevention or relief of one or several symptoms of disease, mediated by CRTH2, associated with eosinophils, basophils, where disease is selected from asthma, allergic asthma, asthma of physical effort, allergic rhinitis, atopic dermatitis, contact hypersensitivity and hyper IgE syndrome.

EFFECT: invention relates to novel pharmaceutically acceptable salts, containing pharmaceutically acceptable amine, selected from ethylenediamine, piperazine, benzathine or choline and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5yl}acetic acid.

43 cl, 21 dwg, 4 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel crystalline forms I, II and amorphous form of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid.

EFFECT: invention relates to pharmaceutical composition, containing crystalline form I of compound and to application of crystalline form I for treatment, prevention or relief of one or more symptoms of disease, mediated by CRTH2, associated with eosinophils, basophils, where disease is selected from asthma, allergic asthma, asthma, induced by physical effort, allergic rhinitis, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity.

16 cl, 11 dwg, 8 tbl,11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a quinazoline derivative of general formula [1], or a pharmaceutically acceptable salt thereof [1], where R1-R6 assume values given claim 1, except compounds in which R5 is hydrogen and R6 is -NH2. The invention also relates to a pharmaceutical composition having the activity of an antipruritic agent, containing as an active ingredient said quinazoline derivative or pharmaceutically acceptable salt thereof.

EFFECT: obtaining a novel quinazoline derivative with low irritant action on skin and excellent action of significant suppression of scratching behaviour, as well as an antipruritic agent containing such a quinazoline derivative as an active ingredient.

9 cl, 250 ex, 7 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted pyrimidine derivatives having PGDS inhibiting properties. In formula (I): (I), R1 denotes phenyl or a 5- or 6-member heteroaryl containing 1-3 heteroatoms selected from N, O and S, each optionally having one or more of the following independent substitutes: halogen, (C1-C6)-alkyl, or (C1-C4)-haloalkyl; R2 denotes hydrogen or (C1-C6)-alkyl, which is optionally substituted with one or more halogens; R3 denotes hydrogen, (C1-C6)-alkyl or phenyl; R4 denotes C6-cycloalkyl, phenyl, a 6-member heterocyclyl containing one N heteroatom, a 6-member heteroaryl containing one N heteroatom, -C(=O)-NY1Y2, -C(=S)-NY1Y2, or -C(=O)-R5, where the phenyl, 6-member heteroaryl or 6-member heterocyclyl group optionally has one or more independent substitutes R6, or R3 and R4 together with a nitrogen atom with which they are bonded form a 5- or 6-member heterocyclyl containing one or two heteroatoms selected from N, O and S, a 6-member heterocyclenyl containing two or three N heteroatoms, a 5-member monocyclic or 9-member bicyclic heteroaryl containing one to three N heteroatoms, phenylheterocyclyl, where the heterocyclyl is 5- or 6-membered and contains one or two heteroatoms selected from N and O, each optionally having one or more independent substitutes R6. Values of R5, R6, Y1, Y2 are given in the claim. The invention also relates to a pharmaceutical composition containing said compounds.

EFFECT: improved method.

15 cl, 227 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

EFFECT: there are produced new benzimidazole derivatives showing PPARγ modulatory activity.

41 cl, 2 dwg, 6 tbl, 76 ex

FIELD: chemistry.

SUBSTANCE: invention relates to 2,3-substituted pyrazine sulphonamides of formula (I), use thereof in treating allergic diseases, inflammatory dermatosis, immonological disorders and neurodegenerative disorders, as well as pharmaceutical compositions, having CRTH2 receptor inhibiting action and inhibiting chemoattractant receptor, homologous to the molecule expressed on T-helpers 2. in general formula .

A is selected from a group consisting of

, n denotes an integer independently selected from 0, 1, 2, 3 or 4; m equals 1 or 2; B is selected from a group consisting of phenyl or piperazinyl; R1 denotes hydrogen; R2 denotes phenyl, where R2 is optionally substituted with one or more substitutes selected from a group consisting of halogen, cyano, (C1-C6)alkyl; R3 is selected from a group consisting of (C1-C6)alkyl, aryl, heteroaryl, (C1-C6)alkylaryl, (C1-C6)alkylheteroaryl, (C3-C8)cycloalkyl and (C3-C8)heterocycloalkyl, where each of said (C1-C6)alkyl, aryl, heteroaryl, (C1-C6)alkylaryl, (C1-C6)alkylheteroaryl, (C3-C8)cycloalkyl and (C3-C8)heterocycloalkyl is optionally substituted with one or more substitutes selected from a group consisting of halogen, cyano, (C1-C6)alkyl, (C1-C6)alkoxy, heteroaryl, aryl, thioalkoxy and thioalkyl, or where said aryl, heteroaryl, (C1-C6)alkylaryl, (C1-C6)alkylheteroaryl, (C3-C8)cycloalkyl or (C3-C8)heterocycloalkyl can be condensed with one or more aryl, heteroaryl, (C3-C8)cycloalkyl or (C3-C8)heterocycloalkyl groups and can be substituted with one or more substitutes selected from a group consisting of (C1-C6)alkyl, alkoxy, aryl, heteroaryl, carboxyl, cyano, halogen, hydroxy, amino, aminocarbonyl, nitro, sulphoxy, sulphonyl, sulphonamide and trihaloalkyl; R7 is selected from a group consisting of hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, aryl, heteroaryl, (C3-C8)cycloalkyl, (C3-C8)heterocycloalkyl, carboxyl, cyano, amino and hydroxy; aryl is selected from phenyl or naphthyl; and heteroaryl is selected from pyridyl, indolyl, 3H-indolyl, benzimidazolyl, quinolizinyl.

EFFECT: high efficiency of using the compounds.

4 cl, 10 dwg, 46 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a new acid dihydrogenphosphate of 2-(3-{6-[2-(2,4-dichlorophenyl)ethylamino]-2-methoxypyrimidine-4-yl}phenyl)-2-methylpropionic acid of formula optionally in a crystalline form exhibiting cAMP inhibitor properties. Also, the invention refers to a pharmaceutical composition.

EFFECT: compound can find application for treating the diseases associated with cell expression of prostaglandin D2 in such diseases, as allergic rhinitis, bronchial asthma, allergic conjunctivitis, etc.

3 cl, 12 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is presented is a method of treating chronic adenoiditis in children. A real-time polymerase chain reaction is used to analyse the blood serum concentrations of interleukine-1β and interleukine-4. Observing the C/C genotype of interleukine-1β gene in locus 3954 in a combination with the C/C or C/T genotype of interleukine-4 gene in locus 589 enables diagnosing a severe clinical course of chronic adenoiditis with frequent aggravations, complications requiring the treatment including intranasal inhalations of the suspension of mometasone 50-100 mcg per a procedure into each nasal passage 1-2 times a day 100-400 mcg daily for 30 days. Observing the C/T genotype of interleukine-1β gene in locus 3954 in a combination with the C/C or C/T genotype of interleukine-4 gene in locus 589 enables diagnosing a moderate severity of chronic adenoiditis with aggravated recurrences that requires the treatment including intranasal inhalations of the suspension of mometasone 50 mcg per a procedure into each nasal passage 1 time a day 100 mcg daily for 21-30 days. Observing the T/T genotype of interleukine-1β gene in locus 3954 in a combination with the C/C or C/T genotype of interleukine-4 gene in locus 589 enables diagnosing a mild severity of chronic adenoiditis with a mild clinical course and a favourable outcome, treated by intranasal lyophilised interleukine-1β in physiological solution 5-10 ng/ml per a procedure into each nasal passage once a day with a daily dose to be increased by 5-10 ng/ml every 1-2 days, but no more than 30 ng/ml for 5-16 days.

EFFECT: invention provides stratifying the risk groups with chronic adenoiditis and provides the effective method of treating chronic adenoiditis in children.

8 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to organic chemistry, namely to new 1,2-dihydroquinoline derivatives of general formula , or to a pharmaceutically acceptable salt thereof, wherein R1 represents a lower alkyl group; R2 represents a hydrogen atom; each of R3 and R4 represents a lower alkyl group; R5 represents a lower alkyl group; R6 represents a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group; X represents -CO-, -C(O)NR8 - or -S(O)2-; each of R7 and/or R8 may be identical or different, and represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower cycloalkyl group, a phenyl or naphthyl group, a saturated or unsaturated monocyclic 5- or 6-member heterocyclyl with one or two heteroatoms specified in nitrogen, oxygen and sulphur atoms, and 3-5 carbon atoms in a cycle, a lower alkoxy group, a phenoxy group; provided R7 and/or R8 represent a lower alkyl group, a lower alkoxy group, the mentioned lower alkyl group and lower alkoxy group may contain one or three groups specified in a halogen atom, a phenyl group, an unsubstituted monocyclic 6-member heterocyclyl with one heteroatom specified in a nitrogen atom, and 5 carbon atoms in a cycle, a lower alkoxy group, and -NRaRb as a substitute (substitutes); provided R7 and/or R8 represent a phenyl group, a saturated or unsaturated monocyclic 5- or 6-member heterocyclyl with one or two heteroatoms specified in nitrogen, oxygen and sulphur atoms, and 3-5 carbon atoms in a cycle, a phenoxy group, the mentioned phenyl group, saturated or unsaturated monocyclic 5- or 6-member heterocyclyl with one or two heteroatoms specified in nitrogen, oxygen and sulphur atoms, and 3-5 carbon atoms in a cycle, phenoxy group may contain one or two groups specified in a halogen atom, a lower alkyl group, a halogen-substituted lower alkyl group, a phenyl group, a hydroxyl group, a lower alkoxy group, a halogen-substituted lower alkoxy group, a lower alkylthio group, a lower alkylcarbonyl group, a lower alkoxycarbonyl group, a lower alkylcarbonyloxy group, -NRaRb, a nitro group and a cyano group as a substitute (substitutes); Ra and Rb may be identical or different, and each of them represents a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group; Y represents a lower alkylene group; Z represents an oxygen atom; p is equal to 2, provided p is equal to 2, R6 may be identical or different. The invention also relates to a pharmaceutical composition and a glucocorticoid receptor modulator of the compound of formula (1).

EFFECT: there are produced new 1,2-dihydroquinoline derivatives possessing glucocorticoid receptor binding activity.

7 cl, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely otolaryngology, and may be used for treating rhinitis. That is ensured by rinsing both halves of the nasal cavity with an infusion of sage leaves, camomile blossom, plantain leaves with the plants to be alternated daily. Then 30 minutes after the rinsing, 5 ml of an aqueous solution containing 5 doses of Lactobacterinum are instilled into the nasal cavity. There are 3-4 instillations needed, a half of a dropper in each half of the nose with the dropper touching the wing of the nose. The procedure is repeated 2-5 times a day. The therapeutic course makes 6 to 21 days.

EFFECT: method provides the higher therapeutic effect ensured by antiseptic, anti-inflammatory and mucolytic action of the herbal infusions used and the replacement of a pathological flora by a normal one, the natural stimulation of the immune processes accompanied by the reduced drug load and risk of developing side effects.

3 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and may be used for treating odontogenous maxillary sinusitis. That is ensured by the conventional antibacterial anti-inflammatory therapy with maxillary sinus and catheterisarion for sinus dialysis. The anti-inflammatory therapy is conducted by treating a system of root canals and a periapical site of infection at the last stage of treating granuloma, cyst and polyp by laser coagulation for 1 minute and hermetic canal filling. Output diode laser power is 3-3.5 Wt, wave length is 980 nm in a pulse mode. Polyps 0.5 cm are eliminated within a sinus bottom after remitting of the acute inflammatory process by the photodynamic therapy. Photoditasine 1.5-2.0 ml is introduced into the sinus by means of the catheter. After the 5-minute exposition, the sinus bottom is exposed to diode laser for 5-7 minutes at output power 2-3 Wt, wave length 810 nm in the pulse mode. The polyps more than 0.5 cm require polypectomy.

EFFECT: method enables reducing length of treatment, eliminating operative intervention and intraoperative and postoperative complications.

1 ex

Pressed tablets // 2472491

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a pressed tablet containing a pressed non-chewable base and a volatile active agent, preferentially menthol or eucalyptol included in a spray-dried granule additionally containing a starch carrier and a polyol granulating agent. The pressed tablet may be a two-layer tablet containing a sparkling layer and a non-sparkling layer with the spray-dried granule included in the sparkling layer. The tablets in the present application are effective to provide decongestant effects in a nasal cavity.

EFFECT: invention additionally refers to the use of starch for increasing release rate of the volatile active agent from the pressed tablet and improving its disintegration smoothness.

12 cl, 3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to homogenous pharmaceutical composition for treatment of inflammatory disorders, which contains mixture of steroid anti-inflammatory or anti-histamine active ingredient in pharmaceutically acceptable water carrier with liposome. As steroid anti-inflammatory ingredient used is budesonide or fluticasone or their pharmaceutically acceptable salt, and antihistamine preparation is represented by azelastine or its pharmaceutically acceptable salt, concentration of active ingredient in water carrier is, in fact, equal inside and outside liposomic structures and varies ±20% when concentration of active ingredient inside and outside liposomic structures is compared. Polar lipid is swellable in water and represents phospholipid or glycosphingolipid. Invention also relates to method of composition obtaining, which lies in joint mixing of polar lipid, water phase and said active ingredient and mixture homogenising. Invention also relates to method of treating inflammatory disorders, including introduction of claimed composition to individuum, suffering from or sensitive to said disorders.

EFFECT: invention ensures reduction of irritation, for instance, in case of nasal introduction of composition.

52 cl, 9 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to otolaryngology, and deals with immunotherapy of purulent rhinosinusitis. Method is based on data of genotyping by signs of allele polymorphism of cytokine gene, obtained in analysis of blood cells and cells isolated from washings from sinuses. If high-producing allele of gene LL-β "2/2" and low-producing allele of gene TL-1RA "1/1" are identified in patient, immunotherapy with preparation of recombinant 1L-1RA, conditioned by regulation of activation of phagocytic activity of neutrophils, is performed.

EFFECT: method ensures efficient treatment of patients with lingering course of disease, who cannot be treated by traditional methods of therapy, due to individual selection of immunopreparation taking into account immunogenetic peculiarities of organism.

6 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely pulmonology, reflexotherapy. The method involves the needle exposure on acupuncture points and the introduction of diprospan. The first, third, sixth, seventh, ninth and twelfth sessions involves the needles covering the acupuncture points P 5 (2) and GI 4 (2). On the second session, the needle exposure involves the points GI 11 (2) in a prone position with hands up, and diprospan 0.25 ml injected in the points V 11 (2) and V 13 (2). The fourth and tenth sessions imply the needle exposure on the points P 5 (2), P 7 (2). The fifth session includes the needle therapy in the points GI 11 (2), and diprospan 0.5 ml is injected in the points V 13 (2). On the eighth session, there is used the needle therapy in the points GI 11 (2) in a prone position with hands up, and also in the points V 11 (2) and V 13 (2). The eleventh session involves the needle exposure on the points GI 11 (2) and V 13 (2).

EFFECT: method prolongs the remission.

3 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically, to infectious diseases, and can be used for staphylococcal bacilli carrier sanitation. For this purpose the carrier state profile is determined in bacilli carriers by anti-carnosine activity of S.aureus. Treatment of the anterior nose area is performed in resident bacilli carriers using Cycloferon liniment drug q.d. for 6 days, whereafter bacteriologic examination is carried out. Upon the absence of S.aureus or if the intensity level of their anti-carnosine activity is less than 1.8 mg/ml, sanitation is considered as positive.

EFFECT: method allows for performance of effective staphylococcal bacilli carrier sanitation with specification of carrier state profile due to reduction of staphylococci anti-carnosine activity, owing to which pathogenic flora elimination from schneiderian membrane is achieved.

1 dwg, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: claimed is application of solid peroral dosing composition of prolonged action, which includes (a) core, containing effective amount of pseudoephedrine or its salt, (b) first envelope, covering core and including swelling in water film-forming neutral or cationogenic copolymer ester, film modifier and lubricating substance, and (c) second envelope, covering first envelope and including effective amount of desloratadine, amount of pseudoephedrine or its salt is sufficient for ensuring maximaum of average geometrical values of pseudoephedrine concentration in plasma, from 345 to 365 ng/ml, for the time from 7.60 to 8.40 h, and amount of desloratadine is sufficient for ensuring maximum of its average geometrical values of concentration in plasma, from 2.10 to 2.45 ng/ml, for period from 4.0 to 4.5 h after intake of single dose of said composition, for preparation of medication for treatment of allergic and/or inflammatory states of upper and lower respiratory ways and skin, or urticaria and nasal and non-nasal symptoms of year-round and seasonal allergic rhinitis.

EFFECT: composition ensures necessary profile of active agents release and is efficient in treatment of allergic bronchospasm, couphing, seasonal allergic rhinites.

3 cl, 4 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: dry powder composition for pulmonary inhalation Parkinson's disease contains apomorphine and magnesium stearate with a nominal dose of apomorphine being 3 to 10 mg and providing a dose of fine particle fraction (FPF) making 2 to 6 mg when administered. A method for preparing the composition involves the stages of combining the apomorphine particles with the magnesium stearate particles by mixing and milling, milling including compression.

EFFECT: composition under the invention contains apomorphine in a stable dry powder form suitable for the direct administration of low doses of the drug with minimal adverse side effects.

15 cl, 12 dwg, 13 tbl, 12 ex

Up!